干旱区生态环境知识资源中心(Arid): PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY

Arid

DOI	10.1097/IAE.0000000000002599
	PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY
	Mein, Calvin; Dugel, Pravin U.; Feiner, Leonard; Drenser, Kim; Miller, Daniel; Benz, Matthew; Meunier, Esmeralda; Moro, Lionel; Fineman, Mitchell S.
通讯作者	Mein, C
来源期刊	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
ISSN	0275-004X
EISSN	1539-2864
出版年	2020
卷号	40 期号:7 页码:1331-1338
英文摘要	Purpose: To evaluate patient-reported visual function after ocriplasmin through the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) in patients with symptomatic vitreomacular adhesion/vitreomacular traction including macular hole. Methods: This was a prespecified analysis of a secondary endpoint from the OASIS trial. Patients received a single intravitreal injection of ocriplasmin (0.125 mg) or sham and completed the VFQ-25 questionnaire at baseline and at Months 6, 12, and 24. Clinically meaningful (>= 5-point) changes from baseline were assessed. Results: Of the 220 patients enrolled, 146 received ocriplasmin and 74 received sham. At Month 24, the percentage of patients with a >= 5-point improvement from baseline in VFQ-25 composite scores was higher with ocriplasmin versus sham (51.4% vs. 30.1%, 95% confidence interval, 8.1-34.5,P= 0.003). The percentage of patients with >= 5-point worsening at Month 24 was lower with ocriplasmin versus sham (9.5% vs. 15.6%, 95% confidence interval: -15.6 to 3.5,P= 0.191). A larger percentage of patients treated with ocriplasmin versus sham experienced a >= 5-point improvement in VFQ-25 composite and subscale scores at Month 24 regardless of baseline full-thickness macular hole status. Conclusion: A larger percentage of patients with symptomatic vitreomacular adhesion/vitreomacular traction reported clinically meaningful improvements in self-assessed visual function with ocriplasmin than sham.
英文关键词	OASIS ocriplasmin patient-reported outcomes symptomatic vitreomacular adhesion VFQ-25 vitreomacular traction
类型	Article
语种	英语
开放获取类型	Green Published
收录类别	SCI-E
WOS记录号	WOS:000546379800015
WOS关键词	TRACTION ; OUTCOMES ; RELEASE
WOS类目	Ophthalmology
WOS研究方向	Ophthalmology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/324959
作者单位	[Mein, Calvin] Retinal Consultants San Antonio, 9480 Huebner Rd,Suite 310, San Antonio, TX 78240 USA; [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA; [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA 90007 USA; [Feiner, Leonard] Hackensack Univ Med Ctr, Hackensack, NJ USA; [Feiner, Leonard] NJ Retina, Ridgewood, NJ USA; [Drenser, Kim] Associated Retinal Consultants PC, Royal Oak, MI USA; [Miller, Daniel] Cincinnati Eye Inst, Cincinnati, OH USA; [Benz, Matthew] Retinal Consultants Houston, Houston, TX USA; [Meunier, Esmeralda; Moro, Lionel] Oxurion, Leuven, Belgium; [Fineman, Mitchell S.] Mid Atlantic Retina, Philadelphia, PA USA; [Fineman, Mitchell S.] Wills Eye Hosp & Res Inst, Philadelphia, PA USA
推荐引用方式 GB/T 7714	Mein, Calvin,Dugel, Pravin U.,Feiner, Leonard,et al. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY[J],2020,40(7):1331-1338.
APA	Mein, Calvin.,Dugel, Pravin U..,Feiner, Leonard.,Drenser, Kim.,Miller, Daniel.,...&Fineman, Mitchell S..(2020).PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY.RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES,40(7),1331-1338.
MLA	Mein, Calvin,et al."PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY".RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES 40.7(2020):1331-1338.